Adaptive Biotechnologies Corp
ADPT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001478320
In the last 90 days, Adaptive Biotechnologies Corp insiders filed 0 open-market purchases and 14 sales; 301 institutions reported holding it in 13F filings for Q2 2026, worth $3.34B in total; superinvestors Viking Global Investors and ARK Invest hold it.
13F holders, Q2 2024
Institutional positions in Adaptive Biotechnologies Corp as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 177
- −12 vs. Q1 2024
- Shares held
- 148.8M
- +6.37M (+4.5%) vs. Q1 2024
- Total value
- $538.6M
- +$81.6M (+17.9%) vs. Q1 2024
- New holders
- 25
- 70 more added
- Sold out
- 37
- 45 more reduced
1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ADPT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 301 | $3.34B |
| Q1 2026 | 299 | $2.11B |
| Q4 2025 | 284 | $2.44B |
| Q3 2025 | 271 | $2.18B |
| Q2 2025 | 242 | $1.73B |
| Q1 2025 | 225 | $1.14B |
| Q4 2024 | 207 | $858.6M |
| Q3 2024 | 187 | $732.5M |
| Q2 2024 | 177 | $538.6M |
| Q1 2024 | 190 | $457.4M |
| Q4 2023 | 200 | $704.0M |
| Q3 2023 | 191 | $769.4M |
| Q2 2023 | 210 | $920.9M |
| Q1 2023 | 227 | $1.18B |
| Q4 2022 | 223 | $1.01B |
| Q3 2022 | 226 | $931.2M |
| Q2 2022 | 210 | $1.08B |
| Q1 2022 | 221 | $1.74B |
| Q4 2021 | 214 | $3.46B |
| Q3 2021 | 220 | $4.00B |
| Q2 2021 | 231 | $4.80B |
| Q1 2021 | 249 | $4.58B |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Adaptive Biotechnologies Corp; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Quantbot Technologies LP | 0 | $0 | 0.00% | −26,474−100.0% | Sold out |
| Pier 88 Investment Partners LLC | 0 | $0 | 0.00% | −26,415−100.0% | Sold out |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 0 | $0 | 0.00% | −21,364−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −17,036−100.0% | Sold out |
| Great West Life Assurance Co | 0 | $0 | 0.00% | −12,950−100.0% | Sold out |
| Envestnet Asset Management Inc | 0 | $0 | 0.00% | −12,120−100.0% | Sold out |
| Point72 (DIFC) Ltd | 0 | $0 | 0.00% | −11,731−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −10,800−100.0% | Sold out |
| Melfa Wealth Management, LLC | 0 | $0 | 0.00% | −10,100−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −3,808−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −3,462−100.0% | Sold out |
| Banque Cantonale Vaudoise | 0 | $0 | 0.00% | −300−100.0% | Sold out |
| Assetmark, Inc | 0 | $0 | 0.00% | −80−100.0% | Sold out |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 0 | $0 | 0.00% | −24−100.0% | Sold out |
| Credit Suisse AG | – | – | – | – | Not filed |